Best Chemotherapy for prostate cancer Doctors Worldwide — TOP 50

Prof. Merimsky leads the Soft Tissue and Bone Oncology Unit at Sourasky Medical Center, with decades of expertise in sarcoma and prostate cancer treatments.

• Associate Professor of Oncology at Sackler Faculty of Medicine
• Fellowship-trained at Institut Gustave Roussy in Paris
• Active member of ESMO and ASCO
• Published extensively on oncology outcomes
• Head of Oncology Outpatient Clinic at Sourasky

Dr. Sarid specializes in chemotherapy for prostate cancer at Sourasky Medical Center, with over 38 years of experience of focused oncology experience.

• Senior oncologist at Sourasky (Ichilov) Medical Center since 2009
• Principal investigator of clinical trials in cancer therapies
• Published over 30 articles on cancer treatment
• Member of The European Society for Medical Oncology

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.

He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Prof. Sezer Sağlam specializes in medical oncology with a focus on prostate cancer at Gayrettepe Florence Nightingale Hospital.

• Professor of Medical Oncology since 2016
• Fellowship-trained at Istanbul University Medical Faculty
• Member of ESMO, ASCO, and Turkish Medical Oncology Association
• Attending physician in Gastrointestinal Oncology at Istanbul University

Dr. Osama Abdel Mohimen Mohamed leads the Hematology Unit at Shefaa Al Orman Oncology Hospital. He treats complex blood cancers, including leukemia, lymphoma, and myeloma. Dr. Mohamed is a member of the European Society for Medical Oncology. He also holds memberships in the American Society of Hematology and ASBMT.

• Specializes in chemotherapy, immunotherapy, and bone marrow transplantation.
• Manages aggressive acute leukemia and chronic blood disorders.
• Treats complications arising from various solid tumors.
• Works at an ESMO-accredited center that handles 6,000 patients annually.

Dr. Zamboglou leads the prostate cancer research group at the University of Freiburg and is an invited expert for German and European prostate cancer guidelines.

• Board-certified in radiotherapy and radiation oncology
• Holds a habilitation (postdoctoral qualification) from the University of Freiburg
• Recipient of the prestigious Herman-Holthusen Award from DEGRO
• Vice Medical Director at German Medical Institute in Cyprus
• Member of ESTRO-ACROP guideline committee for prostate cancer

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Sinan Karaaslan is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, colorectal, and urogenital system cancers. Dr. Karaaslan brings clinical expertise from major institutions, including Medical Park and Gülhane Military Medical Academy. He works at a hospital affiliated with the Johns Hopkins Hospital.

• Holds personal certification from the European Society for Medical Oncology.
• Treats complex conditions, including stage 4 colon and lung cancers.
• Member of the Turkish Medical Oncology and Turkish Lung Cancer societies.
• Performs systemic therapies such as immunotherapy, targeted therapy, and chemotherapy.

Dr. Solak specializes in chemotherapy for prostate cancer, with training at Hacettepe University Cancer Institute and MD Anderson Cancer Center.

• Completed fellowship at Hacettepe University Cancer Institute
• Worked at The University of Texas MD Anderson Cancer Center
• Experienced in treating various cancers including prostate cancer
• Specializes in breast, testicular, ovarian, lung, and gastrointestinal cancers

Professor Yesim Yildirim specializes in cancer immunotherapy and targeted therapies, with over 80 international publications and co-authorship in major oncology handbooks.

• Member of European Society of Medical Oncology (ESMO)
• Professor at Halic University with extensive academic credentials
• Specializes in breast, gastrointestinal, and lung cancers
• Completed advanced oncology training at Rambam Medical Centre in Israel

Assoc. Prof. Dr. Heves Sürmeli is a specialist in Internal Medicine and Medical Oncology. She received her medical degree (M.D.) from Eskişehir Osmangazi University in 2004. She completed her Internal Medicine residency at Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul (2005–2010). She then completed subspecialty training in Medical Oncology at the same hospital (2014–2017).

At the same center, she served as a Medical Oncology Specialist (2017–2023). She then worked as Administrative and Clinical Director (2023–2026). Her clinical interests include breast, lung, gynecologic, gastrointestinal, and urologic cancers.

She has published many articles in international peer‑reviewed journals. She has presented at national and international conferences. She is active in professional societies. She has received several awards.

Dr. Seref Komurcu is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, lung, colorectal, and solid cancers. Dr. Komurcu holds both ECFMG and ESMO certifications. He previously served as a professor at Gülhane Military Medical Academy.

• Published over 110 scientific papers on cancer management.
• Provides immunotherapy, targeted therapy, and chemotherapy treatments.
• Member of the American Society of Clinical Oncology.
• Works at a clinic affiliated with Johns Hopkins Medicine.

Dr. Eda Tanrikulu is a clinical oncologist at Anadolu Medical Center in Istanbul. She ranked 3rd nationally in Turkey's minor specialty medical exam. Dr. Tanrikulu specializes in chemotherapy and individualized cancer treatments. She works at a facility affiliated with the Johns Hopkins Hospital.

• Served as the head of the medical oncology unit at Haydarpaşa Numune Hospital.
• Participated in global training at Oxford University and ESMO in Manchester.
• Treats gastrointestinal, urological, lung, and breast cancers.
• Member of the American and European Societies of Medical Oncology.

Dr. Necdet Uskent is a medical oncologist and hematologist at Anadolu Medical Center in Istanbul. He was part of the pioneering team that performed Turkey's first bone marrow transplant. Dr. Uskent holds the European Medical Oncology Certificate and focuses on breast, lung, and gastrointestinal cancers. He works at a facility affiliated with Johns Hopkins Medicine.

• Founder of the Turkish Oncology Group (TOG).
• A founding member of the Turkish Society of Medical Oncology.
• Served as a visiting lecturer at Royal Free and University College Hospital in London.
• Treats complex hematological conditions including lymphomas and myeloma.

Specializing in gastrointestinal oncology, Dr. Sezer Saglam leads at Gayrettepe Florence Nightingale Hospital.

• Professor of medical oncology with extensive experience
• Active member of ESMO and ASCO
• Fellowship-trained at Istanbul University Oncology Institute

Chief Physician at a certified cancer center with 14 years of experience in oncology – Phd Viola Fox specializes in advanced prostate cancer treatments.

• Expert in chemotherapy, immunotherapy, and targeted therapies
• Qualified specialist in genetics for personalized treatment plans
• Active researcher in molecular biology for innovative cancer therapies
• Member of German and American oncology associations

Associate Professor Tahsin Ozatli specializes in breast, lung, and gastrointestinal cancers at Istinye Liv University Hospital.

• Over a decade of experience in oncology
• Worked at Ankara Oncology Clinic and Erzurum Regional Training and Research Hospital
• Promoted to Associate Professor in 2016
• Trained at Selcuk University Faculty of Medicine

Professor Cemil Bilir specializes in medical oncology with a focus on prostate cancer at VM Medical Park Pendik Hospital.

• Over 21 years of experience of experience in medical oncology
• Trained at Cleveland Clinic and Northeastern University
• Member of ASCO, ESMO, and TTOD
• Currently a professor at Sakarya University